JP2022548270A5 - - Google Patents

Info

Publication number
JP2022548270A5
JP2022548270A5 JP2022516687A JP2022516687A JP2022548270A5 JP 2022548270 A5 JP2022548270 A5 JP 2022548270A5 JP 2022516687 A JP2022516687 A JP 2022516687A JP 2022516687 A JP2022516687 A JP 2022516687A JP 2022548270 A5 JP2022548270 A5 JP 2022548270A5
Authority
JP
Japan
Prior art keywords
nucleic acid
fxn
human
promoter
acid construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022516687A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548270A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050551 external-priority patent/WO2021050991A1/en
Publication of JP2022548270A publication Critical patent/JP2022548270A/ja
Publication of JP2022548270A5 publication Critical patent/JP2022548270A5/ja
Pending legal-status Critical Current

Links

JP2022516687A 2019-09-13 2020-09-11 フリードライヒ運動失調症の治療のための組成物及び方法 Pending JP2022548270A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962899953P 2019-09-13 2019-09-13
US62/899,953 2019-09-13
PCT/US2020/050551 WO2021050991A1 (en) 2019-09-13 2020-09-11 Compositions and methods for treatment of friedreich's ataxia

Publications (2)

Publication Number Publication Date
JP2022548270A JP2022548270A (ja) 2022-11-17
JP2022548270A5 true JP2022548270A5 (cg-RX-API-DMAC7.html) 2023-07-25

Family

ID=74865919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516687A Pending JP2022548270A (ja) 2019-09-13 2020-09-11 フリードライヒ運動失調症の治療のための組成物及び方法

Country Status (6)

Country Link
US (1) US20220211737A1 (cg-RX-API-DMAC7.html)
EP (1) EP4028027A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022548270A (cg-RX-API-DMAC7.html)
AU (1) AU2020346914A1 (cg-RX-API-DMAC7.html)
CA (1) CA3151073A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021050991A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023077123A1 (en) * 2021-11-01 2023-05-04 University Of Florida Research Foundation, Incorporated Aav-mediated therapies for vision loss associated with friedreich's ataxia
CN120417914A (zh) * 2022-11-01 2025-08-01 普利维尔治疗公司 用于治疗弗里德赖希共济失调的组合物和方法
WO2025157942A2 (en) * 2024-01-23 2025-07-31 Icm (Institut Du Cerveau Et De La Moelle Épinière) Encapsulated engineered cells for treating a disease or condition affecting the nervous system

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3632923A1 (en) * 2015-01-16 2020-04-08 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
EP3286321A4 (en) * 2015-04-24 2018-10-17 University of Florida Research Foundation, Inc. Aav vector for treatment of friedreich's ataxia
AU2016343979A1 (en) * 2015-10-29 2018-05-10 Voyager Therapeutics, Inc. Delivery of central nervous system targeting polynucleotides
SG10201912763QA (en) * 2015-11-05 2020-02-27 Bamboo Therapeutics Inc Modified friedreich ataxia genes and vectors for gene therapy
AU2017359342B2 (en) * 2016-11-09 2022-02-17 Intrexon Corporation Frataxin expression constructs
US10780183B2 (en) * 2017-06-19 2020-09-22 Translate Bio, Inc. Messenger RNA therapy for the treatment of Friedreich's ataxia
WO2019000093A1 (en) * 2017-06-29 2019-01-03 UNIVERSITé LAVAL PLATINUM TALE AND USE THEREOF TO INCREASE THE EXPRESSION OF FRATAXIN
PL3697914T3 (pl) * 2017-10-17 2023-10-16 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol Wektory do leczenia ataksji friedreicha

Similar Documents

Publication Publication Date Title
JP2022508182A5 (cg-RX-API-DMAC7.html)
JP2022535749A5 (cg-RX-API-DMAC7.html)
JP6516713B2 (ja) アデノ随伴ウイルス(aav)の同源系統群(クレイド)、配列、それらを含有するベクターおよびそれらの用途
JP2024009857A5 (cg-RX-API-DMAC7.html)
EP2675484B1 (en) Improved aav8 vector with enhanced functional activity and methods of use thereof
JP2021512649A5 (cg-RX-API-DMAC7.html)
JP2022524434A5 (cg-RX-API-DMAC7.html)
JP2022529631A5 (cg-RX-API-DMAC7.html)
WO2018200419A1 (en) Viral vectors comprising engineered aav capsids and compositions containing the same
JP2025515979A5 (cg-RX-API-DMAC7.html)
JP2022551744A5 (cg-RX-API-DMAC7.html)
JP2019513399A5 (cg-RX-API-DMAC7.html)
JP7541027B2 (ja) 筋肉発現のためのハイブリッドプロモーター
JP2017510298A5 (cg-RX-API-DMAC7.html)
IL299325B1 (en) Variants of acid alpha-glucosidase and their uses
US11891616B2 (en) Transgene cassettes designed to express a human MECP2 gene
JP2020509786A5 (cg-RX-API-DMAC7.html)
JP2022525302A5 (cg-RX-API-DMAC7.html)
JP2023537358A5 (cg-RX-API-DMAC7.html)
KR20250102136A (ko) 중추 신경계에서의 유전자 발현을 위한 핵산 조절 요소 및 사용 방법
JP2023059858A5 (cg-RX-API-DMAC7.html)
JP2023542211A5 (cg-RX-API-DMAC7.html)
US20210180084A1 (en) Gene therapy vectors comprising s/mar sequences
JP2023520763A5 (cg-RX-API-DMAC7.html)
JP2023542131A5 (cg-RX-API-DMAC7.html)